Summary of clinical results

Clinical study on the safety and efficacy of SENSINOL Spray SOS
Dermatologically-controlled clinical study of the safety and efficacy of SENSINOL Spray SOS in adults with sensitive scalps.
Population
35 subjects included.
77% women/23% men (20 - 66 years) with a sensitive scalp:
3S score > 2
Application of SENSINOL Spray SOS
At least 1 application a day for the1st week, then 3 times a week for the following 2 weeks.
Evaluation criteria
- Scoring by the subject :
o Self-assessment questionnaire on the impact of 5 sensations (itching, tingling, pulling, pain, burning) on quality of life (3S Score)
o Self-assessment of intensity of burning, pain, xerosis and scalp comfort (visual analog scale from 0 to 10)
o Cosmetic acceptability questionnaire - Skin tolerance
Results
Immediate action: highly significant reduction in intensity score of burning sensations, pain, xerosis andscalp comfort after the1st application (p < 0.001 vs. D1).
Evolution of the intensity score of burning sensations, pain, xerosis and scalp comfort (VAS 0-10) after the first application (D1 Timm)

Intensification of effect after 21-day treatment: highly significant reduction in intensity score of burning sensations, pain, xerosis and scalp comfort(p < 0.001 vs D1).
Evolution of the intensity score of burning sensations, pain, xerosis and scalp comfort (VAS 0-10) after the 21-day treatment phase

Highly significant reduction in the impact of scalp pruritus on quality of lifeafter 21 days of treatment : overall 3S score reduced by 78% at D22 (p < 0.001 vs. D1).
Evolution of the 3S score during the 21-day treatment phase

Very good cosmetic acceptability after 21 days of treatment.
100% of subjects appreciated the non-greasy texture of the product applied to the scalp.
Excellent skin tolerance.
Conclusion
SENSINOL Spray SOS : soothing effect on the scalp from the1st application. Significant improvement in quality of life associated with scalp pruritus after 3 weeks of treatment.
More summaries of clinical results
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.